Themis Medicare Ltd
Themis Medicare Ltd Q2 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY25 Net Revenue: Rs. Q2 FY25 Financials: - EBITDA: Rs.
From Themis Medicare Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Net Revenue: Rs. 117.01 Cr, up 11.67% YoY from Rs. 104.78 Cr in Q2 FY24 (Page 8).
- H1 FY25 Net Revenue: Rs. 240.00 Cr, up 19.15% YoY from Rs. 201.43 Cr in H1 FY24 (Page 9).
- Formulation Segment grew >36% YoY in Q2 FY25 (Page 8).
- Hospital Business grew over 13% YoY in Q2 FY25 (Page 6, 8).
- Trade Business grew over 45% YoY in Q2 FY25 (Page 6, 8).
- Incremental sales from higher-realization products and productivity focus contributed to margin improvement despite API pricing pressures (Page 8).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key investor presentation takeaways from Wockhardt
- Anuh Pharma Ltd (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY25 investor presentation — and how it ranks against sec
- Lincoln Pharmaceuticals Ltd (Q2 FY25)
EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga
- Fermenta Biotech Ltd (Q2 FY25)
Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) . Key investor presentation takeaways from Fermenta Biotech Ltd's Q2 FY25 inv
Frequently Asked Questions
What were Themis Medicare Ltd Q2 FY25 results?
Q2 FY25 Net Revenue: Rs. Q2 FY25 Financials: - EBITDA: Rs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The investor presentation does not explicitly detail specific capex amounts, capacity expansions, or new plant/project initiatives with timelines.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.